Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | LIBE | BONI Michał ( PPE) | |
Committee Opinion | ENVI |
Lead committee dossier:
Legal Basis:
EC Treaty (after Amsterdam) EC 039
Legal Basis:
EC Treaty (after Amsterdam) EC 039Events
PURPOSE: to subject 4-methylamphetamine to control measures.
NON-LEGISLATIVE ACT: Council Implementing Decision (EU) 2015/1874 on subjecting 4-methylamphetamine to control measures.
CONTENT: the Council adopted an implementing decision on subjecting 4-methylamphetamine to control measures across the Union.
4-methylamphetamine is a synthetic ring-methylated derivative of amphetamine. It has emerged on the illicit amphetamine market where it is sold and used as the controlled drug, amphetamine.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
A risk assessment report on 4-methylamphetamine was drawn up in accordance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
The report revealed that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance. However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union.
Decision 2013/129/EU ceases to produce effects as of the day of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting that new psychoactive substance to control measures and criminal penalties in their national laws.
ENTRY INTO FORCE: 21.10.2015.
The European Parliament adopted by 649 votes to 6, with 34 abstentions, a legislative resolution on the draft Council implementing decision on subjecting 4-methylamphetamine to control measures.
In line with the Committee on Civil Liberties, Justice and Home Affairs, the European Parliament approved the Council draft aiming to subject 4-methylamphetamine to control measures.
The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Michał BONI (EPP, PL) on the draft Council implementing decision on subjecting 4methylamphetamine to control measures.
The committee approved the Council draft which seeks to invite the Member States to subject the new psychoactive substance 4-methylamphetamine to control measures across the Union.
In compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substance 4-methylamphetamine . The risk assessment report was subsequently submitted to the Commission and to the Council on 29 November 2012.
PURPOSE: to subject 4-methylamphetamine to control measures.
PROPOSED ACT: Implementing Council Decision.
ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.
BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substance 4-methylamphetamine . The risk assessment report was subsequently submitted to the Commission and to the Council on 29 November 2012.
4-methylamphetamine is a synthetic ring-methylated derivative of amphetamine. It has emerged on the illicit amphetamine market where it is sold and used as the controlled drug, amphetamine.
There has been one report of the substance being detected in a commercial product sold on the internet.
According to the limited data sources available, the acute toxicity of 4-methylamphetamine is similar to that of other stimulants. There have been a total of 21 fatalities registered in four Member States where 4-methylamphetamine alone, or in combination with one or more substances, especially amphetamine, has been detected in post-mortem samples.
4-methylamphetamine has been detected in 15 Member States, while one Member State has reported the manufacture of the substance on its territory. Eight Member States control the substance under drug control legislation. The information available suggests that 4-methylamphetamine is produced and distributed by the same organised crime groups that are involved in the manufacture and trafficking of amphetamine.
The Risk Assessment Report reveals that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance.
However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union. As a result of the health risks it poses, as documented by its detection in several reported fatalities, especially when used in combination with other substances, of its strong resemblance in terms of appearance and effects with amphetamine, of the fact that users may unknowingly consume the substance, and of its limited medical value or use, 4-methylamphetamine should be subjected to control measures across the Union.
CONTENT: this proposal aims to invite the Member States to subject the new psychoactive substance 4-methylamphetamine to control measures across the Union .
Decision 2013/129/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-methylamphetamine to control measures and criminal penalties in their national laws.
The United Kingdom shall not take part in the adoption of this Decision and is not bound by it or subject to its application.
PURPOSE: to subject 4-methylamphetamine to control measures.
PROPOSED ACT: Implementing Council Decision.
ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.
BACKGROUND: in compliance with Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances, the Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) assessed the risks on the new psychoactive substance 4-methylamphetamine . The risk assessment report was subsequently submitted to the Commission and to the Council on 29 November 2012.
4-methylamphetamine is a synthetic ring-methylated derivative of amphetamine. It has emerged on the illicit amphetamine market where it is sold and used as the controlled drug, amphetamine.
There has been one report of the substance being detected in a commercial product sold on the internet.
According to the limited data sources available, the acute toxicity of 4-methylamphetamine is similar to that of other stimulants. There have been a total of 21 fatalities registered in four Member States where 4-methylamphetamine alone, or in combination with one or more substances, especially amphetamine, has been detected in post-mortem samples.
4-methylamphetamine has been detected in 15 Member States, while one Member State has reported the manufacture of the substance on its territory. Eight Member States control the substance under drug control legislation. The information available suggests that 4-methylamphetamine is produced and distributed by the same organised crime groups that are involved in the manufacture and trafficking of amphetamine.
The Risk Assessment Report reveals that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance.
However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union. As a result of the health risks it poses, as documented by its detection in several reported fatalities, especially when used in combination with other substances, of its strong resemblance in terms of appearance and effects with amphetamine, of the fact that users may unknowingly consume the substance, and of its limited medical value or use, 4-methylamphetamine should be subjected to control measures across the Union.
CONTENT: this proposal aims to invite the Member States to subject the new psychoactive substance 4-methylamphetamine to control measures across the Union .
Decision 2013/129/EU ceases to produce effects from the date of entry into force of this Decision, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-methylamphetamine to control measures and criminal penalties in their national laws.
The United Kingdom shall not take part in the adoption of this Decision and is not bound by it or subject to its application.
Documents
- Final act published in Official Journal: Decision 2015/1874
- Final act published in Official Journal: OJ L 275 20.10.2015, p. 0035
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament: T8-0326/2015
- Committee report tabled for plenary, 1st reading/single reading: A8-0265/2015
- Committee draft report: PE564.978
- Legislative proposal: 10010/2015
- Legislative proposal published: 10010/2015
- Legislative proposal: 10010/2015
- Committee draft report: PE564.978
Activities
- Marina ALBIOL GUZMÁN
Plenary Speeches (1)
- Jean ARTHUIS
Plenary Speeches (1)
- Marie-Christine ARNAUTU
Plenary Speeches (1)
- Jonathan ARNOTT
Plenary Speeches (1)
- Zigmantas BALČYTIS
Plenary Speeches (1)
- Hugues BAYET
Plenary Speeches (1)
- José BLANCO LÓPEZ
Plenary Speeches (1)
- Steeve BRIOIS
Plenary Speeches (1)
- Gianluca BUONANNO
Plenary Speeches (1)
- James CARVER
Plenary Speeches (1)
- Nicola CAPUTO
Plenary Speeches (1)
- Salvatore CICU
Plenary Speeches (1)
- David COBURN
Plenary Speeches (1)
- Alberto CIRIO
Plenary Speeches (1)
- Therese COMODINI CACHIA
Plenary Speeches (1)
- Javier COUSO PERMUY
Plenary Speeches (1)
- Michel DANTIN
Plenary Speeches (1)
- William (The Earl of) DARTMOUTH
Plenary Speeches (1)
- Gérard DEPREZ
Plenary Speeches (1)
- Marielle DE SARNEZ
Plenary Speeches (1)
- Norbert ERDŐS
Plenary Speeches (1)
- Georgios EPITIDEIOS
Plenary Speeches (1)
- Edouard FERRAND
Plenary Speeches (1)
- Lorenzo FONTANA
Plenary Speeches (1)
- Doru-Claudian FRUNZULICĂ
Plenary Speeches (1)
- Elena GENTILE
Plenary Speeches (1)
- Arne GERICKE
Plenary Speeches (1)
- Tania GONZÁLEZ PEÑAS
Plenary Speeches (1)
- Brian HAYES
Plenary Speeches (1)
- Marian HARKIN
Plenary Speeches (1)
- Pablo IGLESIAS
Plenary Speeches (1)
- Diane JAMES
Plenary Speeches (1)
- Marc JOULAUD
Plenary Speeches (1)
- Ivan JAKOVČIĆ
Plenary Speeches (1)
- Philippe JUVIN
Plenary Speeches (1)
- Barbara KAPPEL
Plenary Speeches (1)
- Afzal KHAN
Plenary Speeches (1)
- Giovanni LA VIA
Plenary Speeches (1)
- Marine LE PEN
Plenary Speeches (1)
- Monica MACOVEI
Plenary Speeches (1)
- Ivana MALETIĆ
Plenary Speeches (1)
- Andrejs MAMIKINS
Plenary Speeches (1)
- Dominique MARTIN
Plenary Speeches (1)
- Notis MARIAS
Plenary Speeches (1)
- Barbara MATERA
Plenary Speeches (1)
- Stefano MAULLU
Plenary Speeches (1)
- David MARTIN
Plenary Speeches (1)
- Jean-Luc MÉLENCHON
Plenary Speeches (1)
- Miroslav MIKOLÁŠIK
Plenary Speeches (1)
- Louis MICHEL
Plenary Speeches (1)
- Bernard MONOT
Plenary Speeches (1)
- Marlene MIZZI
Plenary Speeches (1)
- Sophie MONTEL
Plenary Speeches (1)
- Franz OBERMAYR
Plenary Speeches (1)
- Rolandas PAKSAS
Plenary Speeches (1)
- Alojz PETERLE
Plenary Speeches (1)
- Florian PHILIPPOT
Plenary Speeches (1)
- Marijana PETIR
Plenary Speeches (1)
- Andrej PLENKOVIĆ
Plenary Speeches (1)
- Salvatore Domenico POGLIESE
Plenary Speeches (1)
- Franck PROUST
Plenary Speeches (1)
- Liliana RODRIGUES
Plenary Speeches (1)
- Claude ROLIN
Plenary Speeches (1)
- Fernando RUAS
Plenary Speeches (1)
- Lola SÁNCHEZ CALDENTEY
Plenary Speeches (1)
- Remo SERNAGIOTTO
Plenary Speeches (1)
- Jill SEYMOUR
Plenary Speeches (1)
- Maria Lidia SENRA RODRÍGUEZ
Plenary Speeches (1)
- Siôn SIMON
Plenary Speeches (1)
- Branislav ŠKRIPEK
Plenary Speeches (1)
- Davor ŠKRLEC
Plenary Speeches (1)
- Beatrix von STORCH
Plenary Speeches (1)
- Richard SULÍK
Plenary Speeches (1)
- Eleftherios SYNADINOS
Plenary Speeches (1)
- Adam SZEJNFELD
Plenary Speeches (1)
- Pavel TELIČKA
Plenary Speeches (1)
- Mylène TROSZCZYNSKI
Plenary Speeches (1)
- Ángela VALLINA
Plenary Speeches (1)
- Miguel VIEGAS
Plenary Speeches (1)
- Jana ŽITŇANSKÁ
Plenary Speeches (1)
Votes
A8-0265/2015 - Michał Boni - Vote unique #
History
(these mark the time of scraping, not the official date of the change)
docs/0 |
|
events/0/date |
Old
2015-06-30T00:00:00New
2015-06-29T00:00:00 |
docs/0/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE564.978New
https://www.europarl.europa.eu/doceo/document/LIBE-PR-564978_EN.html |
events/1/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Committee referral announced in Parliament |
events/2/type |
Old
Vote in committee, 1st reading/single readingNew
Vote in committee |
events/3/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/A-8-2015-0265_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/A-8-2015-0265_EN.html |
events/5 |
|
events/5 |
|
procedure/Modified legal basis |
Rules of Procedure EP 159
|
procedure/Other legal basis |
Rules of Procedure EP 159
|
committees/0 |
|
committees/0 |
|
events/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0265&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-8-2015-0265_EN.html |
events/5/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0326New
http://www.europarl.europa.eu/doceo/document/TA-8-2015-0326_EN.html |
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
docs |
|
events |
|
links |
|
other |
|
procedure/Modified legal basis |
Old
Rules of Procedure of the European Parliament EP 150New
Rules of Procedure EP 159 |
procedure/dossier_of_the_committee |
Old
LIBE/8/03853New
|
procedure/final/url |
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1874New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32015D1874 |
procedure/subject |
Old
New
|
procedure/subtype |
Old
Consultation of ParliamentNew
|
procedure/summary |
|
procedure/title |
Old
Implementing decision on subjecting 4-methylamphetamine to control measuresNew
Subjecting 4-methylamphetamine to control measures |
activities/5 |
|
activities/6 |
|
procedure/final |
|
procedure/stage_reached |
Old
Awaiting final decisionNew
Procedure completed |
activities/4/docs/0 |
|
activities/4/type |
Old
Decision by Parliament, 1st reading/single readingNew
Results of vote in Parliament |
activities/0/commission/0 |
|
activities/1/committees/1/date |
2015-09-03T00:00:00
|
activities/1/committees/1/rapporteur |
|
activities/2 |
|
activities/3 |
|
activities/4 |
|
committees/1/date |
2015-09-03T00:00:00
|
committees/1/rapporteur |
|
other/0 |
|
procedure/Modified legal basis |
Rules of Procedure of the European Parliament EP 150
|
procedure/stage_reached |
Old
Awaiting committee decisionNew
Awaiting final decision |
activities/0/docs/0/text |
|
activities |
|
committees |
|
links |
|
other |
|
procedure |
|